BioWorld

Jan. 15, 2008

Inspire Drops Bilastine, but all Eyes are on Denufosol

Inspire Pharmaceuticals Inc.'s decision to discontinue development of the oral antihistamine bilastine for allergic rhinitis was "no surprise" to Cowen & Co. analyst Ian Sanderson. (BioWorld Today) Read More

Compugen, Merck Sign GPCR Ligand Discovery Collaboration

Scaffolds Could Aid Transplants, Stem Cell Plasticity Research

FDA OKs Tysabri for Crohn's Disease

Panel Gives Cell Genesys OK to Continue Prostate Trial

Clinic Roundup

Financings Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Aug. 20, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Aug. 20, 2025.

CSL to shave off 3,000 jobs, Seqirus vaccine unit

BioWorld

CSL Ltd.’s stock tumbled 16.88% on the news that it plans to cut 3,000 jobs and to hive off its Seqirus vaccine unit in a cost-cutting measure to save more than...

Illustration of magnifying glass inspecting brain

Subtyping beats a path toward precision medicine in Alzheimer’s

BioWorld MedTech

Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding subtypes in Alzheimer’s disease is all...

Elderly woman holding illustration of brain with missing puzzle piece

Marvel Biotechnology’s MB-204 as therapeutic agent for Alzheimer’s disease

BioWorld Science

Phosphorylation of the protein Tau is a key post-translational feature in tauopathies like Alzheimer’s disease (AD), which leads to microtubule dysfunction and...